An investigation of the interaction between halofantrine, CYP2D6 and CYP3A4: studies with human liver microsomes and heterologous enzyme expression systems.

1. We have assessed the interaction of the antimalarial halofantrine with cytochrome P450 (CYP) enzymes in vitro, with the use of microsomes from human liver and recombinant cell lines. 2. Rac-halofantrine was a potent inhibitor (IC50 = 1.06 microM, Ki = 4.3 microM) of the 1-hydroxylation of bufuralol, a marker for CYP2D6 activity. Of a group of structurally related antimalarials tested, only quinidine (IC50 = 0.04 microM) was more potent. 3. Microsomes prepared from recombinant CYP2D6 and CYP3A4 cell lines were shown to catalyse halofantrine N-debutylation. 4. The metabolism of halofantrine to its N-desbutyl metabolite by human liver microsomes showed no correlation with CYP2D6 genotypic or phenotypic status and there was no consistent inhibition by quinidine. 5. The rate of halofantrine metabolism showed a significant correlation with both CYP3A4 protein levels (r = 0.88, P = 0.01) and the rate of felodipine metabolism (r = 0.86, P = 0.013), a marker substrate for CYP3A4 activity. Inhibition studies showed that ketoconazole is a potent inhibitor of halofantrine metabolism (IC50 = 1.57 microM). 6. In conclusion, we have demonstrated that halofantrine is a potent inhibitor of CYP2D6 in vitro and can also be metabolised by the enzyme. However, in human liver microsomes it appears to be metabolised largely by CYP3A4.

[1]  D. Back,et al.  Metabolism of the contraceptive steroid desogestrel by human liver in vitro. , 1990, Journal of steroid biochemistry.

[2]  J. Idle,et al.  Pharmacogenetic Phenotyping and Genotyping , 1994, Clinical pharmacokinetics.

[3]  B. Summers,et al.  Debrisoquine hydroxylase gene polymorphism and susceptibility to Parkinson's disease , 1992, The Lancet.

[4]  F. Guengerich,et al.  Selective inhibitors of cytochromes P450. , 1994, Toxicology and applied pharmacology.

[5]  T. Cosgriff,et al.  Evaluation of the antimalarial activity of the phenanthrenemethanol halofantrine (WR 171,669). , 1982, The American journal of tropical medicine and hygiene.

[6]  Nico P. E. Vermeulen,et al.  A preliminary 3D model for cytochrome P450 2D6 constructed by homology model building , 1993, J. Comput. Aided Mol. Des..

[7]  H. Yamazaki,et al.  Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. , 1994, The Journal of pharmacology and experimental therapeutics.

[8]  G. Edwards,et al.  Determination of halofantrine and its principal metabolite desbutylhalofantrine in biological fluids by reversed-phase high-performance liquid chromatography. , 1988, Journal of chromatography.

[9]  H. Towbin,et al.  Immunoblotting and dot immunobinding--current status and outlook. , 1984, Journal of immunological methods.

[10]  K. Brøsen,et al.  A dose-effect study of the in vivo inhibitory effect of quinidine on sparteine oxidation in man. , 1990, British journal of clinical pharmacology.

[11]  D A Smith,et al.  Speculations on the substrate structure-activity relationship (SSAR) of cytochrome P450 enzymes. , 1992, Biochemical pharmacology.

[12]  F. Guengerich,et al.  Development of a pharmacophore for inhibition of human liver cytochrome P-450 2D6: molecular modeling and inhibition studies. , 1993, Journal of medicinal chemistry.

[13]  L. Bertilsson,et al.  Extensive metabolizers of debrisoquine become poor metabolizers during quinidine treatment. , 1987, Pharmacology & toxicology.

[14]  U. K. Laemmli,et al.  Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4 , 1970, Nature.

[15]  D. Kyle,et al.  Cardiac effects of antimalarial treatment with halofantrine , 1993, The Lancet.

[16]  G. Baker,et al.  Analysis of imipramine and three metabolites produced by isozyme CYP2D6 expressed in a human cell line. , 1993, Xenobiotica; the fate of foreign compounds in biological systems.

[17]  S A van Acker,et al.  A predictive model for substrates of cytochrome P450-debrisoquine (2D6). , 1992, Chemical research in toxicology.

[18]  H. Yamazaki,et al.  Bufuralol hydroxylation by cytochrome P450 2D6 and 1A2 enzymes in human liver microsomes. , 1994, Molecular pharmacology.

[19]  K. Goa,et al.  Halofantrine , 2012, Drugs.

[20]  W. Kalow,et al.  Competitive inhibition of sparteine oxidation in human liver by beta-adrenoceptor antagonists and other cardiovascular drugs. , 1984, Life sciences.

[21]  W. Trager,et al.  Isoform-selective mechanism-based inhibition of human cytochrome P450 1A2 by furafylline. , 1993, Chemical research in toxicology.

[22]  I. Kanazawa,et al.  Evidence for a new variant CYP2D6 allele CYP2D6J in a Japanese population associated with lower in vivo rates of sparteine metabolism. , 1993, Pharmacogenetics.

[23]  C. Broom.  Human pharmacokinetics of halofantrine hydrochloride , 1989 .

[24]  F. Gonzalez,et al.  Molecular genetics of the debrisoquin‐sparteine polymorphism , 1991, Clinical pharmacology and therapeutics.

[25]  U. Meyer,et al.  Multiple mutations of the human cytochrome P450IID6 gene (CYP2D6) in poor metabolizers of debrisoquine. Study of the functional significance of individual mutations by expression of chimeric genes. , 1990, The Journal of biological chemistry.

[26]  J. Kolars,et al.  Identification of rifampin-inducible P450IIIA4 (CYP3A4) in human small bowel enterocytes. , 1992, The Journal of clinical investigation.

[27]  O. H. Lowry,et al.  Protein measurement with the Folin phenol reagent. , 1951, The Journal of biological chemistry.

[28]  J. Le bras,et al.  In vitro activity of the enantiomers of mefloquine, halofantrine and enpiroline against Plasmodium falciparum. , 1992, British journal of clinical pharmacology.

[29]  J. Karbwang,et al.  Cardiac effect of halofantrine , 1993, The Lancet.

[30]  T. Kronbach,et al.  High-performance liquid chromatographic assays for bufuralol 1'-hydroxylase, debrisoquine 4-hydroxylase, and dextromethorphan O-demethylase in microsomes and purified cytochrome P-450 isozymes of human liver. , 1987, Analytical biochemistry.

[31]  J. S. Miles,et al.  Relative expression of cytochrome P450 isoenzymes in human liver and association with the metabolism of drugs and xenobiotics. , 1992, The Biochemical journal.

[32]  M. Sari,et al.  Oxidation of dihydropyridine calcium channel blockers and analogues by human liver cytochrome P-450 IIIA4. , 1991, Journal of medicinal chemistry.

[33]  Kenneth J. Fishman,et al.  Comparison of urinary 6‐β‐cortisol and the erythromycin breath test as measures of hepatic P450IIIA (CYP3A) activity , 1992, Clinical pharmacology and therapeutics.

[34]  R J Edwards,et al.  Determination of human hepatic cytochrome P4501A2 activity in vitro use of tacrine as an isoenzyme-specific probe. , 1995, Drug metabolism and disposition: the biological fate of chemicals.

[35]  S. Wrighton,et al.  The human hepatic cytochromes P450 involved in drug metabolism. , 1992, Critical reviews in toxicology.

[36]  T. Omura,et al.  THE CARBON MONOXIDE-BINDING PIGMENT OF LIVER MICROSOMES. I. EVIDENCE FOR ITS HEMOPROTEIN NATURE. , 1964, The Journal of biological chemistry.

[37]  M. Galteau,et al.  Molecular heterogeneity of the XbaI defined 44kb allele of the CYP2D locus within the Caucasian population. , 1993, British journal of clinical pharmacology.

[38]  F. Gonzalez,et al.  Human cytochromes P450: problems and prospects. , 1992, Trends in pharmacological sciences.

[39]  W. Watkins,et al.  Measurement of halofantrine and its major metabolite desbutylhalofantrine in plasma and blood by high-performance liquid chromatography: a new methodology. , 1992, Journal of chromatography.

[40]  T. Kronbach.  Bufuralol, dextromethorphan, and debrisoquine as prototype substrates for human P450IID6. , 1991, Methods in enzymology.

[41]  M D Devous,et al.  Comparison of SPECT applications in neurology and psychiatry. , 1992, The Journal of clinical psychiatry.